canertinib experimental drug candidate treatment cancer irreversible tyrosinekinase inhibitor activity egfr nm nm pfizer discontinued development canertinib reported substrate transporter protein interaction canertinib may alter hepatic disposition lead transporter mediated drugdrug canertinib inhibitor antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikicanertinib